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Group 2 innate lymphoid cells (ILC2s) are abundant in
non-lymphoid tissues and increase following infec-
tious and inflammatory insults. In solid tumors, how-
ever, ILC2s constitute a relatively small proportion of
immune cells. Here, we show, using melanoma as a
model, that while the IL-33/IL C2/eosinophil axis sup-
presses tumor growth, tumor-derived lactate attenu-
ates the function and survival of ILC2s. Melanomas
with reduced lactate production (LDHAlow) are
growth delayed and typified by an increased number
of ILC2s compared with control tumors. Upon IL-33
stimulation, ILC2s accompanied by eosinophils
more effectively restrain the growth of LDHAlow tu-
mors than control melanomas. Furthermore, data-
base analysis reveals a negative correlation between
the expression of LDHA andmarkers associated with
ILC2s and the association of high expression of IL33
and an eosinophil marker SIGLEC8 with better over-
all survival in human cutaneous melanoma patients.
This work demonstrates that the balance between
the IL-33/ILC2/eosinophil axis and lactate produc-
tion by tumor cells regulates melanoma growth.
INTRODUCTION
Innate lymphoid cells (ILCs) are lymphocytes that mirror the phe-
notypes and functions of T cells. However, ILCs lack somatically
rearranged antigen receptors and cell-surface molecules that
identify their immune cell ancestry (Artis and Spits, 2015). Based
on the signature cytokines produced and the developmental tra-
jectories acquired, ILCs have been classified into five subsets:
natural killer (NK) cells, group 1 innate lymphoid cells (ILC1s),
ILC2s, ILC3s and lymphoid tissue inducer (LTi) cells (Spits
et al., 2013; Artis and Spits, 2015; Vivier et al., 2018).Cell Rep
This is an open access article undILC2s depend on GATA3 and RORa for their development
(Spits et al., 2013; Mjosberg et al., 2012; Furusawa et al.,
2013). While described as lineage marker-negative (Lin) cells,
ILC2s express various cell surface markers such as c-Kit
(CD117), Sca1 (Ly6a), KLRG1, ICOS, and IL-7Ra (CD127) (Matt-
ner and Wirtz, 2017; Moro et al., 2010, 2016). ILC2s respond to
the alarmin cytokines interleukin (IL)-33, IL-25, and thymic stro-
mal lymphopoietin (TSLP, combined with IL-33) in addition to
eicosanoids such as prostaglandin D2 and leukotriene D4,
neuropeptides including neuromedin U, and sex hormones
(Kabata et al., 2018). Following activation, they rapidly expand
and produce cytokines such as IL-4, IL-5, IL-9, IL-13, and/or am-
phiregulin (Moro et al., 2010; Neill et al., 2010; Price et al., 2010;
Kabata et al., 2013).
ILC2s are rare in secondary lymphoid organs relative to other
immune cells (Vivier et al., 2016). Instead, they harbor a unique
locationwithin non-lymphoid tissues, especially skin andmucosal
barriers (i.e., respiratory and intestinal mucosa), and in fat-associ-
ated lymphoid clusters (FALCs) in the visceral adipose tissue
(Moro et al., 2010; Hammad and Lambrecht, 2015; Mohapatra
et al., 2016; Von Moltke et al., 2016). ILC2s provide the first line
of defense against helminths and protect the integrity of the
epithelium (Artis and Spits, 2015). They are also implicated in the
regulation of metabolic homeostasis (Brestoff et al., 2015; Sasaki
et al., 2019). Notably, dysregulation of ILC2s has been associated
with the development of autoimmune and inflammatory diseases
(Cephus et al., 2017; Ealey et al., 2017; Ebbo et al., 2017).
Whereas the importance of NK cells in the antitumor response
is firmly rooted, the role of ILC2s remains ambiguous and poorly
understood, partially due to their low abundance in solid tumors
(Mattner and Wirtz, 2017; Wagner et al., 2017; Carrega et al.,
2015). The acquisition of antitumorigenic functions appears
to depend on the context of tumor specificity and signaling
intensity (Wagner et al., 2017). Recent evidence indicates that
metabolic pathways within the tumor microenvironment shape
the diversity of infiltrating immune cells (Biswas, 2015; Chang
et al., 2015; Colegio et al., 2014; Brand et al., 2016; Lyssiotis
and Kimmelman, 2017). However, the extent to which metabolicorts 30, 2743–2757, February 25, 2020 ª 2020 The Author(s). 2743






Figure 1. Rapidly Growing B16F10 Tumors Are Depleted of ILC2s
(A) Representative plots and analysis of ILC2 populations in the skin (n = 6) and subcutaneous (n = 6) and mesenteric adipose tissue (n = 6) from naive and tumor-
bearing mice by flow cytometry.
(legend continued on next page)
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deviations from normal set points affect intratumoral ILC2s has
not yet been assessed.
Glucose uptake and metabolism is accelerated in tumor
cells by an increased expression of glucose transporters and
glycolytic enzymes such as glucose transporter 1 (GLUT1) and
lactate dehydrogenase A (LDHA), respectively (Vander Heiden
et al., 2009; Gatenby and Gillies, 2004; Hay, 2016). In addition,
the continuous export of lactate and protons (lactic acid [LA])
by means of monocarboxylate transporters (MCTs) drives the
glycolytic metabolism forward to adapt to the anabolic demands
of tumor cells (Doherty and Cleveland, 2013). This process leads
to the accumulation of LA and subsequent acidification of the tu-
mor microenvironment (Doherty and Cleveland, 2013; Vander
Heiden et al., 2009; Gatenby and Gillies, 2004; Hay, 2016).
Increased lactate production has been associated with the
enhanced progression of various tumor types, including mela-
noma (Girgis et al., 2014; Walenta et al., 2000; Petrelli et al.,
2015; Hirschhaeuser et al., 2011).
Here, using melanoma as amodel, we unravel an immunosup-
pressive activity imposed on ILC2s by tumor cells through the
accumulation of LA in the tumor microenvironment. We show
that LA inhibited proliferation and cytokine production, and sub-
sequently decreased the survival of ILC2s in vitro. Interference
with this immunosuppressive axis in B16F10melanomas by spe-
cifically knocking down lactate dehydrogenase A (LDHAlow)
significantly increased the number of intratumoral ILC2s.
Following stimulation with IL-33, the expansion of ILC2s within
LDHAlow B16F10 tumors accompanied by eosinophils more
effectively controlled melanoma growth compared with control
tumors. It is worth noting that an analysis of the gene expression
data of human cutaneous melanomas revealed that the expres-
sion of LDHA negatively correlated with markers associated with
ILC2s. Moreover, the high expression of IL33 and an eosinophil
marker SIGLEC8 was associated with better overall survival in
cutaneous melanoma patients, indicating the role of the IL-33/
ILC2/eosinophil axis in anti-melanoma immunity.
Our results identify tumor-derived LA production as a plausible
immunosuppressive mechanism that contributes to the paucity
of intratumoral ILC2s.
RESULTS
Exclusion of Intratumoral ILC2s in B16 Tumors
Given that ILC2s are numerous in certain tissues, we assessed
the number of ILC2s in the skin and subcutaneous and mesen-
teric adipose tissues in naive and tumor-bearing mice using
B16 melanomas as a model. We subcutaneously inoculated
wild-type (WT) C57BL/6 mice with highly malignant B16F10(B) Tumor growth profiles of B16F0 and B16F10 cells (1 3 106 cells per mouse)
(C) Representative flow cytometry plots and quantification of ILC2 populations in
(D) Representative flow cytometry plots and quantification of ILC2 populations in
(E) Tumor growth profiles after subcutaneous injection of B16F0 and B16F10 cell
mice (n = 6–8).
(F) Representative flow cytometry plots and quantification of tumor-infiltrating IL
All of the results from tumor growth studies were combined from two independe
experiment out of two independent experiments. The ‘‘n’’ indicates the number
***p < 0.001 as determined by Student’s t test or one-way ANOVA, followed by Tmelanoma cells (13 106 cells per mouse). On day 11 post-inoc-
ulation, the skin overlying the tumor mass and neighboring sub-
cutaneous adipose tissue, together with mesenteric adipose
tissue, were carefully collected and analyzed for the presence
of ILC2s using flow cytometry. After gating on live and
LinCD45+ cells, the analysis revealed a roughly 3- and 4-fold in-
crease in the number of Sca1+KLRG1+ ILC2s in the skin and sub-
cutaneous adipose tissue from tumor-bearing mice compared
with homeostatic cutaneous and subcutaneous ILC2 popula-
tions, respectively (Figures 1A, upper and center panels, and
S1). In contrast, there was no significant difference in the number
of Sca1+KLRG1+ ILC2s in the mesenteric adipose tissue be-
tween naive and tumor-bearing mice (Figure 1A, lower panel).
Spurred by the observation that the tissues adjacent to the tumor
mass were replete with ILC2s, we next assessed the number of
intratumoral ILC2s. For that reason, we subcutaneously inocu-
latedWTC57BL/6mice with either weakly (B16F0) or highly met-
astatic (B16F10) melanoma cells (1 3 106 cells per mouse). As
expected, B16F10 melanomas grew more rapidly and reached
~1 cm3 (±0.1 cm3, SEM) in size, whereas their less-malignant
counterparts, B16F0 melanomas, reached ~0.4 cm3
(±0.04 cm3, SEM) in size within 11 days post-inoculation (Fig-
ure 1B). Tumors were then collected and analyzed for the pres-
ence of intratumoral ILC2s. While flow cytometric analysis
showed a relatively low abundance of Sca1+KLRG1+ ILC2s in
both tumor types, a significantly lower number of ILC2s was
observed in B16F10 melanomas compared with B16F0 tumors
(Figure 1C). Moreover, Sca1+KLRG1+ ILC2s were entirely or
almost completely depleted in B16F10 melanomas following
sacrifice at a later time point, on day 14 post-inoculation
(Figure 1D).
To exclude the possibility that architectural changes within the
skin surrounding the tumors could influence immune cell infiltra-
tion (Gajewski et al., 2013), we performed a histological analysis
of paraffin-embedded tumor sections. As judged by Picrosirius
Red staining, we found no apparent difference in collagen den-
sity (Figure S2A) within the skin surrounding B16F0 and
B16F10 tumors. However, we did find a decreased number of
dermal adipocytes in the skin surrounding B16F10 tumors, as re-
vealed by immunohistochemical analysis using an antibody
against the lipid droplet-associated protein Perilipin1 (Figures
S2B and S2C). To further characterize tumor-associated adi-
pose tissue, we implanted B16F10 melanoma cells into one of
the anterior subcutaneous adipose tissue depots in WT
C57BL/6 mice, as previously described (Wagner et al., 2012).
Immunohistochemical analysis on day 14 post-inoculation re-
vealed the abundance of IL-33 within subcutaneous adipose tis-
sue from tumor-bearing mice, as particularly exemplified by thesubcutaneously injected into C57BL/6 mice (n = 12–13).
the tumors (n = 7–8) on day 11 post-inoculation.
the tumors (n = 5) on day 14 post-inoculation.
s (13 106 cells per mouse) into immunodeficient Rag2/ and Rag2/Il2rg/
C2 populations (n = 6).
nt experiments. The flow cytometry results shown are from one representative
of biological replicates. p < 0.05 considered significant; *p < 0.05; **p < 0.01;
ukey’s multiple comparisons test. Error bars represent SEMs.
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presence of infiltrating inflammatory cells positively stained for
IL-33 (Figure S2D).
Mirroring the decrease in the number of ILC2s, we found a
reduced number of intratumoral T cells (CD3+ and CD8+ cells)
and myeloid lineage cells (CD11b+ cells) in B16F10 tumors
compared with their less malignant counterparts, B16F0 tumors,
with the exception of macrophages (F4/80+ cells), as their num-
ber remained unchanged (Figures S3A and S3B). Since changes
in vascular endotheliummay influence the growth and contribute
to the observed phenotype of B16F10 tumors, we assessed
blood and lymphatic vessel densities (Lund et al., 2016; Stein-
skog et al., 2016). Although blood vessel density was reduced
in B16F10 tumors compared with their less malignant counter-
parts, as analyzed by the number of CD31+ structures per field
of view, the percentage of area covered by CD31+ structures
was noticeably increased in B16F10 tumors (Figures S3C and
S3D). There was no significant difference in lymphatic vessel
densities, as revealed by the number of Lyve1+ structures
(Figure S3E).
To investigate whether the low abundance of immune cells
within B16F10 tumors could provide a selective growth advan-
tage over their lessmalignant counterparts, we inoculated immu-
nodeficient Rag2/ mice (lacking mature B, T, and NKT cells)
and Rag2/Il2rg/ mice (lacking ILCs, apart from mature B,
T, and NKT cells) with B16 melanoma cells. In contrast to that
in Rag2/ mice, the growth difference between B16F0 and
B16F10melanomaswas lost inRag2/Il2rg/mice (Figure 1E).
Furthermore, flow cytometric analysis confirmed the absence of
ILC2s within both B16F0 and B16F10 tumors in Rag2/Il2rg/
mice (Figure 1F). As observed withWTmice, a significantly lower
number of ILC2s was found in B16F10 melanomas compared
with B16F0 tumors in Rag2/ mice (Figure 1F).
Overall, it is likely that these results rule out the possibility that
the low abundance of ILC2s in B16F10 tumors is due to their
decreased ability to penetrate the tumor tissue. Instead, our
data suggest that the tumormicroenvironment negatively affects
ILC2s to suppress their potential antitumor activity.
IL-33 Controls B16F10 Tumor Growth and Intratumoral
Expansion of ILC2s
To reveal the potential antitumorigenic properties of ILC2s,
we subcutaneously inoculated WT C57BL/6 mice with B16F10Figure 2. B16F10 Tumors Challenged with IL-33 Are Growth Delayed a
(A) Tumor growth profiles of B16F10 cells (1 3 106 cells per mouse) subcutaneo
(B and C) Representative flow cytometry plots and quantification of tumor-infiltra
(D) Tumor growth profiles after subcutaneous injection of B16F10 cells (13 106 ce
subjected to treatment with IL-33 (0.5 mg in 100 mL PBS) or PBS at the time of tu
(E and F) Representative flow cytometry plots and quantification of tumor-infiltra
(G) Tumor growth profiles of B16F10 cells (13 106 cells per mouse) subcutaneous
receptor for IL-33 or wild-type (WT)mice (n = 5–6mice per group). Themice were s
tumor cell injection and every 3 days thereafter (as indicated by the arrows).
(H) Representative flow cytometry plots and quantification of tumor-infiltrating IL
(I) Growth of B16F10 cells (13 106 cells per mouse) subcutaneously inoculated int
were injected either with anti-asialo GM1 (ASGM1) antibody (0.3 mg in 100 mL PB
with IL-33 (0.5 mg in 100 mL PBS) or PBS as indicated by the arrows.
All of the results from tumor growth studies were combined from two independe
experiment out of two independent experiments. The ‘‘n’’ indicates the number
***p < 0.001 as determined by Student’s t test or one-way ANOVA followed by Tmelanoma cells alone (1 3 106 cells per mouse) or together
with ILC2s (1 3 105 cells per mouse). The presence of ILC2s
controlled the growth of B16F10 tumors (Figure 2A), although
the number of intratumoral ILC2s was strikingly decreased on
day 11 post-inoculation. The median number of cells was 91
(n = 6) for Sca1+KLRG1+ ILC2s (Figure 2B). A significant increase
in the number of CD11b+Siglec-F+ eosinophils was observed
in tumors growing with ILC2s compared with tumors growing
alone (Figure 2C).
To experimentally probe the role of IL-33 in the generation of
ILC2-mediated response against B16F10 tumors, we subcuta-
neously inoculated WT C57BL/6 mice with tumor cells (1 3 106
cells per mouse) and intraperitoneally administered IL-33
(0.5 mg in 100 mL PBS) or PBS at the time of inoculation and
every 3 days thereafter. The administration of IL-33 significantly
suppressed the growth of B16F10 melanomas (Figure 2D). In
addition, flow cytometric analysis revealed a striking increase
in the number of Sca1+KLRG1+ ILC2s (Figure 2E) and CD11b+
Siglec-F+ eosinophils (Figure 2F) in B16F10 tumors from IL-33-
treated mice. To determine whether the antitumor activity of
IL-33 is mediated directly or indirectly through binding to its re-
ceptor, we subcutaneously inoculated Il1rl1/ mice (referred
to as ST2/ mice) lacking the functional IL-33 receptor with
B16F10 cells (1 3 106 cells per mouse). In contrast to WT
mice, the difference in tumor growth between mice treated
with IL-33 or PBS was lost in ST2/ mice (Figure 2G). Although
flow cytometric analysis confirmed the increase in the number
of Sca1+KLRG1+ ILC2s in B16F10 tumors from IL-33-treated
WT mice, no difference was observed in tumors implanted
into ST2/ mice, regardless of the type of treatment chosen
(Figure 2H). To exclude the possibility that IL-33 directly acti-
vates T cells or NK cells to mediate the observed antitumor
response, we depleted Rag2/ mice of NK cells using anti-
asialo GM1 (ASGM1) antibody during IL-33 treatment. We found
no difference in the tumor growth between Rag2/ mice
depleted of NK cells and Rag2/ mice that received control
immunoglobulin G (IgG) during IL-33 treatment (Figure 2I).
Nevertheless, tumors in both groups of mice that received IL-
33 treatment grew significantly slower compared with the group
of mice treated with PBS only (Figure 2I).
In addition, histological analysis of tumor sections revealed
the presence of lymphoid clusters surrounding tumors fromnd Enriched with ILC2s and Eosinophils
usly injected alone or admixed with ILC2s (1 3 105 cells per mouse) (n = 11).
ting (B) ILC2s and (C) eosinophils (n = 6).
lls per mouse) into PBS or IL-33-treated C57BL/6 mice (n = 13). The mice were
mor cell injection and every 3 days thereafter (as indicated by arrows).
ting (E) ILC2s and (F) eosinophils. (n = 6).
ly injected either into Il1rl1/mice (referred to as ST2/ mice), which lack the
ubjected to the treatment with IL-33 (0.5 mg in 100 mL PBS) or PBS at the time of
C2s (n = 4).
o Rag2/mice (n = 5–7) depleted of NK cells during IL-33 treatment. The mice
S) or control IgG (0.3 mg in 100 mL PBS) and subjected either to the treatment
nt experiments. The flow cytometry results shown are from one representative
of biological replicates. p < 0.05 considered significant; *p < 0.05; **p < 0.01;
ukey’s multiple comparisons test. Error bars represent SEMs.
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Figure 3. IL-33-Activated ILC2s Integrate within
Lymphoid Clusters Formed Around B16F10
Tumors
(A) Histological analysis of hematoxylin and eosin (H&E)-
stained sections of B16F10 tumors harvested at day 11
post-inoculation from PBS or IL-33-treated mice. ‘‘T’’
indicates tumor. ‘‘*’’ indicates a lymphoid cluster, which
is enlarged in the right panel.
(B) Immunohistochemical analysis of immune infiltrates
integrated within lymphoid clusters formed around tu-
mors from IL-33-treated mice.
(C and D) Immunohistochemical analysis (C) and quan-
tification (D) of MBP+ cells present in the periphery and
throughout the interior of the tumors from PBS- or IL-33-
treated mice (n = 5).
The ‘‘n’’ indicates the number of biological replicates.
p < 0.05 considered significant; ***p < 0.01 as deter-
mined by Student’s t test. The error bars represent
SEMs. The average number of cells from 5 fields of view
per tumor in (D). Scale bars: H&E 100 mm (short) and
50 mm (long); immunohistochemistry (IHC) 100 mm.IL-33-treated WT C57BL/6 mice only, as judged by hematoxylin
and eosin (H&E) staining (Figure 3A). Immunohistochemical anal-
ysis revealed the presence of T cells and eosinophils within clus-
ters and macrophages scattered around (Figure 3B). We found
the number of eosinophils expressing major basic protein
(MBP) in the periphery as well as throughout the interior of the tu-
mors from IL-33-treated mice strikingly increased compared
with PBS-treated mice (Figures 3C and 3D). No statistically sig-
nificant difference in the number of CD3+ or CD8+ cells, however,
was observed in B16F10 tumors from IL-33-treated mice2748 Cell Reports 30, 2743–2757, February 25, 2020compared with controls following immunohis-
tochemical (Figures S4A and S4B) and flow
cytometric analyses (data not shown).
Instead, we found an increased number of
macrophages typified as alternatively acti-
vated by expression of the macrophage
galactose C-type lectin 10A (CLEC10A/
CD301) in tumor samples from IL-33-treated
mice. The majority of CD301+ macrophages,
but not F4/80+ macrophages, were found in
the skin surrounding the tumors (Figures S4C
and S4D). A similar staining pattern was
observed using another marker for alterna-
tively activated macrophages, CD163 (data
not shown).
These results support the notion of an anti-
tumorigenic role of ILC2/eosinophil axis in
melanoma, which can be further enhanced
following IL-33 stimulation.
Tumor Cell-Derived LA has an Inhibitory
Effect on ILC2s
To study interactions between tumor cells and
ILC2s using an in vitro model that replicates
many features of solid tumors in vivo, we
generated spheroids from B16F0 and
B16F10 melanoma cells and co-culturedthem with ILC2s. Within 5 days of incubation, we noticed a sig-
nificant shift in pH, as indicated by a change in the color of me-
dium from red to light yellow in co-cultures of spheroids with
ILC2s (data not shown). More importantly, the presence of
spheroids selectively decreased the number of ILC2s co-
cultured in medium supplemented with IL-2 plus IL-33 but not
IL-2 alone (Figure 4A). We assumed that tumor cell-derived sig-
nals inhibited the proliferation of IL-33-stimulated ILC2s. To test
this possibility, we collected conditioned medium (CM) supple-
mentedwith IL-2 plus IL-33 fromB16F10 cells. CMwas sufficient
A B C
D E F G
H I J K
Figure 4. Lactic Acid (LA) Impairs In Vitro Proliferation, IL-5 Production, and Survival of ILC2s
(A) Quantification of the number of ILC2s co-culturedwith B16F0 or B16F10 spheroids inmedium supplementedwith IL-2 (left) or IL-2 plus IL-33 (right) for a period
of 5 days (n = 3).
(B and C) Assessment of the proliferative potential of ILC2s incubated either in different concentrations of conditioned medium (CM) from B16F10 cells sup-
plemented with IL-2 plus IL-33 (B) and its buffered (pH 7.4) or boiled (100C) derivatives for 24 h (n = 3) (C).
(D) Analysis of IL-5 levels produced by ILC2s cultured for 24 h in CM (n = 3).
(E) Quantification of the number of ILC2s after culture in CM for a period of 5 days (n = 3).
(F) Analysis of the level of LA present in medium from B16F0 and B16F10 spheroids co-cultured with ILC2s in medium supplemented with IL-2 plus IL-33 for a
period of 3 days (n = 3).
(G) Assessment of the proliferative potential of ILC2s incubated in different concentrations of LA and sodium lactate (NaLA) supplemented with IL-2 plus IL-33.
(H and I) Assessment of the proliferative potential of ILC2s incubated in buffered (H, pH 7.4) and acidified (I) medium with varying concentrations of HCl sup-
plemented with IL-2 plus IL-33 (n = 3).
(J) Analysis of IL-5 levels produced by ILC2s cultured for 24 h in 20 mM LA or 20 mM NaLA (n = 3).
(K) Quantification of the number of ILC2s after culture in medium containing 20 mM LA, 20 mM NaLA, or HCl (pH = 6.0) for a period of 5 days (n = 3).
Unless otherwise stated, all of the results are representative of three independent experiments. The ‘‘n’’ indicates the number of technical replicates. p < 0.05
considered significant; *p < 0.05; **p < 0.01; ***p < 0.001 as determined by Student’s t test or one-way ANOVA followed by Tukey’s multiple comparisons test.
Error bars represent SEMs.to inhibit proliferation of ILC2s in a dose-dependent manner (Fig-
ure 4B). The pH of CM was in the range of 6.7–6.8, acidic
compared with that of control medium (pH 7.4) (data not shown).
Because of the shift in pH observed, we next sought to deter-
mine whether the inhibitory effect of CM was linked to the pres-
ence of protons. To prove this hypothesis, we buffered CM to pH
7.4 using sodium hydroxide (NaOH) and noted a significant
reduction in its inhibitory effect (Figure 4C). The suppressive ac-
tivity of CMwas also heat stable since CMmanaged to inhibit the
proliferation of ILC2s after prolonged boiling (Figure 4C). By Gi-emsa staining, we also found that ILC2s cultured in CM were
smaller in size, with a scanty cytoplasm compared with those
incubated in medium supplemented with IL-2 plus IL-33 and
reminiscent of ILC2s cultured with IL-2 alone (Figures S5A and
S5B). Apart frommorphological changes, we examined the cyto-
kine-producing capability of ILC2s. In linewith its inhibitory effect
on proliferation, CM significantly lowered the levels of IL-5 pro-
duced by ILC2s (Figure 4D). Quantification of ILC2s during
long-term culture in CM demonstrated a roughly 3-fold decrease
in the number of viable cells after 5 days, whereas an ~4-foldCell Reports 30, 2743–2757, February 25, 2020 2749
increase was observed following incubation in medium supple-
mented with IL-2 plus IL-33 (Figure 4E). These results suggest
that the suppression of proliferation, IL-5 production, and sur-
vival of ILC2s was initiated by tumor cell-derived signals
reducing the pH.
Warburg observed that cancer cells preferentially convert
glucose into lactate regardless of the amount of oxygen present
(the eponymous ‘‘Warburg effect’’) (Hu et al., 2017; Koppenol et
al., 2011; Vander Heiden et al., 2009; Warburg, 1956). As a result,
cancer cells export lactate together with protons, which in turn
lowers the pH of the tumor microenvironment. Because the sup-
pressive activity of CM from B16F10 cells was heat stable and
linked to the presence of protons, we focused on the possibility
that LA is one of the factors responsible for the constraints
imposed on ILC2s. To this end, we measured the level of LA in
CMfromB16F10melanomacells and found that theconcentration
of LA in CMwas ~20mM (±1mM, SEM) (data not shown). In addi-
tion,we found that the level of LAsignificantly increased inmedium
from B16F10 spheroids co-cultured with ILC2s compared with
B16F0 spheroids (Figure 4F). To assess the suppressive activity
of LA on ILC2 proliferation, we cultured ILC2s in medium contain-
ing different concentrations of LA and sodium lactate (the latter of
which does not lead to acidification of themedium) supplemented
with IL-2 plus IL-33. LA was sufficient to inhibit the proliferation of
ILC2s in a dose-dependent manner, whereas sodium lactate had
no effect (Figure 4G). No difference in the number of proliferating
ILC2s, however, was observed following culture in medium con-
taining 20 mM LA supplemented with IL-2 only (data not shown).
The addition of 20 mM LA lowered the pH of culture media from
pH 7.4 to ~pH 6.0 (data not shown). To study the effect of acidifi-
cation on ILC2 proliferation, we cultured ILC2s in an acidified
medium (pH 6.0) prepared using hydrochloric acid (HCl) and sup-
plemented with IL-2 plus IL-33. We noticed a significant inhibition
of the proliferative potential of ILC2s, which was similar to that of
20 mM LA and was reversed after buffering the medium to pH
7.4 (Figure 4H). The inhibitory effect was dependent on the level
of acidification of the medium since the number of proliferating
ILC2s decreased commensurate with a decline in pH (Figure 4I).
Additionally, 24 h of incubation with 20 mM LA significantly
decreased the production of IL-5 as opposed to 20 mM sodium
lactate (Figure 4J). The morphology of ILC2s also changed, as re-
vealed byGiemsa staining. ILC2s incubated inmediumcontaining
20mMLAorHCl (pH6.0)were smaller in sizecomparedwith those
cultured in medium supplemented with IL-2 plus IL-33 and remi-
niscent of ILC2s incubated in medium supplemented with IL-2
alone (FiguresS5CandS5D). Incontrast, theadditionof20mMso-
dium lactate had no effect on the morphology of ILC2s, which
resembled those stimulated with IL-2 plus IL-33 (Figures S5C
and S5D). Moreover, incubation of ILC2s in medium containing
20mMLA or HCl (pH 6.0) for 24 h did not alter the surface antigen
profile expressed by ILC2s, as revealed by flow cytometric anal-
ysis (Figure S5E). Nevertheless, the quantification of ILC2s
exposed to medium containing 20 mM LA or HCl (pH 6.0) for
5 days demonstrated a roughly 8-fold and 2-fold decrease,
respectively, in the number of viable cells (Figure 4K).
These results identify tumor cell-derived LA as one of the sig-
nals responsible for the suppression of proliferation, IL-5 pro-
duction, and survival of ILC2s.2750 Cell Reports 30, 2743–2757, February 25, 2020LDHAlow Melanoma Is More Vulnerable to Intratumoral
ILC2s
To reveal the in vivo significance of LA, we specifically knocked
down Ldha encoding lactate dehydrogenase A responsible for
the generation of LA from pyruvic acid in B16F10 melanoma
cells. We used small hairpin RNAs (shRNAs) complementary to
Ldha to reduce its expression and established LDHAlow
B16F10 melanoma cells. Cells transfected with unspecific,
scrambled shRNA were used as controls (CTRL). The enzymatic
activity of LDHA assessed by the concentration of LA in cell su-
pernatants revealed the decreased production of lactate by
LDHAlow cells compared with untreated and CTRL B16F10 cells
(Figure S6A). No significant difference in the proliferation was
observed between LDHAlow and CTRL cells in vitro (data not
shown). However, subcutaneous inoculation of WT C57BL6
mice revealed that the growth of LDHAlow tumors was signifi-
cantly delayed compared with that of CTRL tumors (Figure 5A).
On day 11 post-inoculation, a larger number of Sca1+KLRG1+
ILC2s was observed in LDHAlow melanomas compared with
CTRL tumors (Figure 5B). In addition, LDHAlow tumors were en-
riched with CD3+ and CD8+ cells compared with CTRL tumors,
further supporting the idea of the immunosuppressive activity
of tumor-derived LA (Figures S6B and S6C). However, no differ-
ence was observed in the number of F4/80+ macrophages (Fig-
ures S6B and S6C).We next wanted to determine the effect of IL-
33 on the growth of LDHAlow tumors. For that reason, we subcu-
taneously inoculated WT C57BL/6 mice with either LDHAlow or
CTRL B16F10 cells and intraperitoneally administered IL-33
(0.5 mg in 100 mL PBS) or PBS alone at the time of inoculation
and every 3 days thereafter. Intraperitoneal administration of
IL-33 significantly inhibited the growth of LDHAlow tumors
compared with CTRL tumors (Figure 5C). LDHAlow tumors
were also typified by a massive infiltration of Sca1+KLRG1+
ILC2s (Figure 5D). Mirroring the increase in the number of IL-
33-activated ILC2s in LDHAlow tumors, we found an increased
infiltration of eosinophils as determined by immunohistochem-
ical analysis and quantification of MBP+ cells compared with
CTRL tumors (Figures 5E and 5F).
Overall, these data support the idea that tumor-derived LA
production negatively affects ILC2s and their antitumorigenic
function in B16F10 melanoma.
LDHA Expression Correlates Negatively with Markers
Associated with ILC2s in Human Cutaneous Melanomas
Since IL-33 strongly activates ILC2s, we used OncoLnc to
conduct overall survival analysis for IL33 expression in 458 hu-
man skin cutaneous melanoma (SKCM) samples from The Can-
cer Genome Atlas (TCGA) database (Anaya, 2016). We found
that the high expression of IL33was associated with better over-
all survival (p = 0.000535) inmelanoma patients (Figure 6A). Simi-
larly, we found a significant correlation between overall survival
in melanoma patients and the expression of an eosinophil
marker SIGLEC8 (p = 0.000971) (Figure 6B).
To identify the possible source of IL-33, we performed immu-
nohistochemical analysis of sections of paraffin-embedded hu-
man control skin and cutaneous melanoma tissue samples.
Although immunohistochemical analysis of control skin revealed




Figure 5. Inhibited LDHA-Associated LA Production In Vivo Improves Antitumor Efficacy of IL-33-Activated ILC2s
(A) Tumor growth profiles after subcutaneous injection of B16F10 melanoma cells with reduced expression of LDHA (LDHAlow cells) or controls (CTRL) (1 3 106
cells per mouse) into C57BL/6 mice (n = 13–14).
(B) Representative flow cytometry plots and quantification of ILC2 populations in the tumors (n = 6 mice per group).
(C) Growth of LDHAlow or CTRL cells (1 3 106 cells per mouse) subcutaneously injected into C57BL/6 mice (n = 6–8). The mice were subjected either to the
treatment with IL-33 (0.5 mg in 100 mL PBS) or PBS at the time of tumor cell injection and every 3 days thereafter (as indicated by arrows).
(D) Representative flow cytometry plots and quantification of tumor-infiltrating ILC2s (n = 6).
(E and F) IHC analysis (E) and quantification (F) of MBP+ cells present in the periphery and throughout the interior of LDHAlow or CTRL tumors from PBS or IL-33-
treated mice (n = 4–5).
All of the results from the tumor growth studies were combined from two independent experiments. The flow cytometry results shown are from one representative
experiment out of two independent experiments. The ‘‘n’’ indicates the number of biological replicates. p < 0.05 considered significant; *p < 0.05; **p < 0.01; ***p <
0.001 as determined by Student’s t test or one-way ANOVA followed by Tukey’s multiple comparisons test. The error bars represent SEMs. Mean of 5 fields of
view per tumor in (F). Scale bars: 50 mm.endothelial cells, the presence of infiltrating inflammatory cells
positively stained for IL-33 typified the majority of cutaneous
melanomas investigated (14 of 18 samples) (Figure 6C).
To estimate a possible genetic correlation between IL33 and
markers associated with ILC2s, we next analyzed 470 human
SKCM samples from TCGA database. Although none of the
markers used were completely specific to ILC2s, we found strong
correlations with one another among the gene expression levels
of KLRG1, GATA3, CCR6, ICOS, KLRB1, and NCR3 (data not
shown), which we defined here as markers associated with
ILC2s. The gene expression levels of IL33 correlated very strongly
with those of markers associated with ILC2s, indicating a
possible positive impact of IL-33 on tumor-infiltrating ILC2s in
human melanomas (Figure 6D). Furthermore, the expression of
IL33 correlated with that of markers for eosinophils such as
SIGLEC8, ADGRE1, and ITGAM (Figure 6E). The gene expression
levels of IL33 also correlatedwithCD14 (expressed bymonocytesandmacrophages), aswell asCD163andCLEC10A (bothmarkers
expressed by alternatively activated macrophages) (Figure 6F).
Using the same database, we next estimated a possible genetic
correlation between LDHA and markers associated with ILC2s.
We found that the expression of LDHA negatively correlated with
that of markers associated with ILC2s such as KLRG1, GATA3,
CCR6, ICOS, KLRB1, and NCR3 (Figure 6G). In addition, the
expression of LDHA correlated negatively with that of markers
expressed by eosinophils, including SIGLEC8, ADGRE1, and
ITGAM (Figure 6H) and to a lesser extent, CD14 and CLEC10A,
but not that of CD68 (expressed by tissue macrophages) (Fig-
ure 6I). We also found no correlation between the expression of
SIGLEC8 and IL1RL1. Instead,wenoticed the correlation between
the expression of SIGLEC8 and genes encoding a heterodimeric
receptor for IL-5, namely IL5RA and CSF2RB (Figure 6J).
These data are consistent with our findings in the mouse sys-
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2752 Cell Reports 30, 2743–2757, February 25, 2020
antitumorigenic role and that tumor-derived LA may have a
negative effect on tumor-infiltrating ILC2s in human cutaneous
melanomas.
DISCUSSION
An increased lactate production favors the progression and
metastasis of various tumor types, including melanoma (Girgis
et al., 2014; Walenta et al., 2000; Petrelli et al., 2015; Hirsch-
haeuser et al., 2011). While the metabolic reprogramming
enables rapid proliferation, continuous growth, and survival of
tumor cells, the ensuing accumulation of metabolites imposes
considerable constraints on infiltrating immune cells (Biswas,
2015).
In this study, we unraveled an immunosuppressive axis
initiated by melanoma cells on ILC2s. We showed that LA pro-
foundly inhibited the proliferation, cytokine production, and sur-
vival of activated ILC2s in vitro. In vivo interference with LDHA
function in B16F10 tumors also was sufficient to significantly in-
crease the number of intratumoral ILC2s. In turn, ILC2s more
effectively restrained the growth of LDHAlow B16F10melanomas
than control tumors upon IL-33 treatment. Our results corrobo-
rate and extend previous reports demonstrating that LA exerts
inhibitory effects on a range of immune cells. For example, tu-
mor-derived LA impairs the differentiation of dendritic cells
(DCs) (Gottfried et al., 2006). Furthermore, LA inhibits the prolif-
eration of and cytokine release from human T cells in vitro,
whereas tumor lactic acidosis hinders tumor immunosurveil-
lance by T and NK cells and their survival in vivo (Fischer et al.,
2007; Brand et al., 2016). It has been suggested that activated
T cells upregulate glycolytic metabolism, which leads to the pro-
duction of LA, a process that depends on a gradient between
cytoplasmic and extracellular lactate concentrations (Brand
et al., 2016). Subsequently, increased concentrations of extra-
cellular LAmay facilitate its uptake, which lowers the intracellular
pH in T cells and disturbs their energy metabolism, as witnessed
by decreased levels of ATP (Fischer et al., 2007). Consequently,
increased LA concentrations (R20 mM) cause apoptosis of T
and NK cells (Fischer et al., 2007; Brand et al., 2016). In line
with these observations, we found the viability of activated
ILC2s substantially decreased following in vitro exposure to me-
dium containing 20 mM LA or HCl (pH 6.0) for 5 days. However,
tumor-associated macrophages have been found to resist the
apoptosis-inducing effect of LA and acquire a protumorigenic
alternatively activated phenotype (Colegio et al., 2014).Figure 6. LDHA Expression Negatively Correlates with Markers Assoc
(A and B) Overall survival of skin cutaneous melanoma (SKCM) patients genera
assigned into low or high groups, according to the expression level of IL33 and SIG
expression level ranging from 0.32 to 97 were considered low (dotted curve) and
high (solid curve), whereas patients having an SIGLEC8 expression level ranging
expression level ranging from 17 to 1,029 were considered high (solid curve).
(C) IHC analysis of IL-33 expression in human control SKCM samples. Scale bar
(D–F) Correlation of IL33with immune cells markers, including those expressed b
(SIGLEC8, ADGRE1, and ITGAM), and macrophages (CD14, CD163, and CLEC1
(G–I) Correlation of LDHAwith immune cells markers, including those expressed b
(SIGLEC8, ADGRE1, and ITGAM), and macrophages (CD14, CD68, and CLEC10
(J) Correlation of SIGLEC8 with IL1RL1, IL5RA, and CSF2RB. For correlation st
(tumor SKCM–TCGA–470–rsem–tcgars) was used. Pearson’s correlation coefficILC2s rapidly respond to IL-33 through their expression of IL-
33 receptors containing IL1RL1 (also known as ST2). IL-33 is
constitutively present in the nuclei of non-hematopoietic cells,
with particular abundance in certain epithelial and endothelial
cell populations (Molofsky et al., 2015). Because IL-33 lacks an
export signal sequence, the activation of ILC2s within the tumor
microenvironment may be triggered by IL-33 passively released
by necrotic and/or necroptotic cells in damaged tissues sur-
rounding the growing tumor mass (Molofsky et al., 2015). For
example, tumor-associated subcutaneous adipose tissue has
been characterized by a robust infiltration of macrophages, trig-
gered by necrosis and release of another nuclear alarmin,
HMGB1 (Wagner et al., 2013; Wagner and Dudley, 2013). Of
note, we found that the number of dermal adipocytes within
the skin surrounding B16F10 melanomas was decreased
compared with their less malignant and less invasive counter-
parts, B16F0 melanomas. Further analysis of tumor-associated
subcutaneous adipose tissue revealed an abundance of IL-33,
particularly exemplified by the presence of infiltrating inflamma-
tory cells positively stained for IL-33. It is now clear that during
inflammatory response cells of hematopoietic origin, including
mast cells, DCs and macrophages actively secrete IL-33 (Furu-
kawa et al., 2017; Schmitz et al., 2005; Mirchandani et al.,
2012). Therefore, it is unlikely that the low abundance of ILC2s
in B16F10 melanomas is due to the absence of signals involved
in their activation.
The lack of specific immunohistochemical markers for ILC2s
makes it additionally difficult to localize ILC2s within complex tis-
sues such as tumors. However, upon IL-33 treatment, we
observed lymphoid clusters in the skin surrounding implanted
B16F10 melanomas. Although lymphoid clusters were present
within the adjacent tissue, once incorporated into the growing tu-
mor mass, their components will likely be exposed to the condi-
tions within the tumor microenvironment.
The extent to which ILC2s are involved in antitumorigenic
responses remains unclear, as they have been separately
associated with both tumor-promoting as well as tumor-sup-
pressing activities (Mattner and Wirtz, 2017; Wagner et al.,
2017). The acquisition of antitumorigenic functions, however,
seems to depend on the context of tumor specificity, justifying
the reason for the use of melanoma in our study. For example,
ILC2s have been implicated in the suppression of the meta-
static spread of B16F10melanoma cells within the lungs through
IL-5-mediated eosinophilia (Ikutani et al., 2012). In addition,
ILC2s have been shown to eliminate B16F10 melanoma cellsiated with ILC2s in Human Cutaneous Melanomas
ted using the OncoLnc platform. TCGA data of 458 melanoma patients were
LEC8 reported as RNA sequencing (RNA-seq) values. Patients having an IL33
those having IL33 expression level ranging from 97 to 7,618 were considered
from 0 to 17 were considered low (dotted curve) and those having an SIGLEC8
s: 100 mm.
y human ILC2s (KLRG1,GATA3, CCR6, ICOS, KLRB1, and NCR3), eosinophils
0A).
y human ILC2s (KLRG1,GATA3,CCR6, ICOS, KLRB1, andNCR3), eosinophils
A).
udies, dataset acquired from R2 platform containing 470 melanoma patients
ient, r, is shown.
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genetically engineered to express IL-33 (Kim et al., 2016). It
should be noted, however, that those studies did not focus on in-
tratumoral ILC2s or rely on a chronic and non-physiological pro-
duction of IL-33 by transgenic melanoma cells, which signifi-
cantly alters the number of ILC2s in the course of tumor
development. ILC2s may exert their antitumorigenic function
through various means. In tumors engineered to express IL-33,
including B16F10melanomas, infiltration of ILC2s has drastically
reduced the tumor growth and induced tumor-cell specific
apoptosis (Kim et al., 2016). In addition, ILC2s adoptively trans-
ferred into Rag2/Il2rg/mice inhibited the growth of EL4 lym-
phomas expressing IL-33 through CXCR2 signaling (Kim et al.,
2016). In our model, we observed the growth of B16F10 mela-
nomas similarly delayed following co-injection with ILC2s with
tumors typified by an increased number of eosinophils. It re-
mains to be deciphered, however, to what extent ILC2s
contribute to the induction of tumor-cell specific apoptosis.
In addition to immunosuppressive cytokines such as IL-4 and
IL-13, ILC2s produce high levels of IL-5 (Moro et al., 2010). IL-5 is
essential for the expansion of eosinophils, since its localized pro-
duction induces tissue eosinophilia (Sanderson et al., 1985;
Leitch et al., 2009; Rosenberg et al., 2013). An increased inci-
dence of methylcholanthrene (MCA)-induced fibrosarcomas
has been observed in the eosinophil-deficient IL-5/CCL11/
and DdblGATA mice, and this correlated with their reduced
number in the tumors (Simson et al., 2007). Conversely, MCA-
induced tumor incidence and growth have been significantly
suppressed in IL-5-overexpressing transgenic mice associated
with robust eosinophilia in the periphery and throughout the inte-
rior of the tumors (Simson et al., 2007). Of note, the cytotoxic ac-
tivity of eosinophils has been ascribed to the secretory granules
composed of MBP-1 and MBP-2, eosinophil cationic protein,
eosin-derived neurotoxin, and eosinophil peroxidase (Davis
and Rothenberg, 2014). For example, MBP+ eosinophils have
been found to be critical in the clearance of metastatic B16F10
cells in the lungs, whereas the lysates of eosinophils become
cytotoxic when cultured with melanoma cells (Mattes et al.,
2003).
In our model, B16F10 tumors were typified by an increased
infiltration of ILC2s and eosinophils, following IL-33 treatment.
Therefore, the suppressing effect on tumor growth, which we
observed, may be related, in part, to the presence of eosinophils.
Concordantly with this hypothesis, Lucarini et al. (2017) reported
that both B16F10 melanoma growth and metastasis formation
were enhanced upon in vivo depletion of eosinophils using an
anti-Siglec-F antibody. Eosinophils have also been found to
enable T cell responses through the normalization of the tumor
vasculature (Carretero et al., 2016). However, we did not observe
a significant increase in the number of T cells at the time of sac-
rifice, suggesting that we either failed to generate a sufficient
adaptive immune response against implanted melanoma cells
during the course of the experiment or that adaptive immunity
was not involved. The growth of B16F10 tumors has been found
to be greatly impaired following IL-33 treatment ofRag1/mice,
which indicates that the systemic administration of IL-33 can
inhibit melanoma growth solely through the innate immune
system (Long et al., 2018). It has also been revealed that the
depletion of lymphoid cells such as CD4+ T cells, CD8+ T cells,2754 Cell Reports 30, 2743–2757, February 25, 2020or NK cells using anti-CD4, anti-CD8, and anti-ASGM1 anti-
bodies (which may also target other cell types, including macro-
phages; Wiltrout et al., 1985), respectively, does not affect the
growth of B16F10 melanomas and EL4 lymphomas engineered
to express IL-33 (Kim et al., 2016). Similarly, we found no differ-
ence in the growth of B16F10 melanomas between Rag2/
mice depleted of NK cells using anti-ASGM1 antibodies and
Rag2/ mice that received control IgG during IL-33 treatment.
In contrast, Dominguez et al. (2017) have found that the growth
of B16F10 tumors is inhibited in aCD8+ T cell-dependentmanner
(but a CD4+ T cell- and NK cell-independent manner) following
treatment with the IL-33 of mice with already established tumors.
One way to reconcile these contradictory features of IL-33 could
be to recognize the role of the IL-33 concentration in the tumor
microenvironment and the mode and length of administration.
In the skin surrounding the tumors, we noticed an increased
number of macrophages typified as alternatively activated by
the expression of CD301 (Biswas and Mantovani, 2012). It has
already been found that IL-33/ST2 signaling amplifies the prolif-
eration and polarization of alternatively activated macrophages
(Kurowska-Stolarska et al., 2009; Jackson-Jones et al., 2016).
It has also been shown that alternatively activated macrophages
suppress T cell expansion, which could in part explain the lack of
increased T cell responsiveness in our model (Taylor et al., 2006;
Schebesch et al., 1997; Huber et al., 2010; Nair et al., 2009).
Therefore, it is tempting to speculate whether selective depletion
of alternatively activated macrophages could further tip the
scales toward a microenvironment that impedes tumor growth,
especially since some tissue-resident macrophages are rela-
tively long-lived cells (Shaw et al., 2018). Of no less importance
is the fact that we abstained from using the ovalbumin-express-
ing melanoma cells frequently used to augment tumor-specific
adaptive immune responses.
Several immunotherapeutic strategies to treat cancer patients
appear to be dependent upon the preexistence of an immune
infiltrate (Spranger et al., 2015; Ji et al., 2012; Tumeh et al.,
2014). Using a cohort of 458 cutaneous skin melanoma patients,
we demonstrated that the expression of IL33 and SIGLEC8 is
associated with better overall survival. The expression of IL33
correlated positively, whereas that of LDHA correlated nega-
tively with markers associated with human ILC2s and eosino-
phils. Therefore, our results indicate that the expression of
LDHA may serve as a predictive marker of ILC2 infiltration in
human melanomas. It should also be noted, however, that no
correlation was observed between the expression levels of
IL33 and SIGLEC8 and overall survival for some other tumors
such as lung squamous cell carcinoma and pancreatic adeno-
carcinoma (data not shown), suggesting that the antitumor
activity of ILC2s is tumor-type specific.
It remains to be deciphered how other metabolic factors and
hypoxia affect ILC2s within the tumor microenvironment
(Wagner and Koyasu, 2019). Our results identify the tumor-
derived LA production as a plausible immunosuppressive
mechanism that contributes to the paucity of intratumoral
ILC2s. With an increasing understanding of the immune sys-
tem, it remains to be seen to what extent the antitumorigenic
potential of ILC2s can be used for the development of new
immunotherapies.
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Proliferation Assay (MTS)
Promega Catalog# G3580
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Eight-week-old male or retired female C57BL/6 mice were purchased from Charles River Laboratories, Japan or CLEA, Japan and
maintained under specific pathogen-free conditions in the animal facility at the RIKEN Center for Integrative Medical Sciences, Yo-
kohama, Japan. Retired female mice, defined as C57BL/6 mice older than four months of age and withdrawn from any furtherCell Reports 30, 2743–2757.e1–e5, February 25, 2020 e2
breeding, were used for ILC2 isolation.Rag2/ (stock no. RAGN12) andRag2/Il2rg/ (stock no. 4111) mice were purchased from
Taconic. Il1rl1/ mice on a C57BL/6 background were a kind gift from Dr. K. Nakanishi of the Hyogo College of Medicine, Nishino-
miya, Japan. Eight-to-twelve-week-old male mice were used for tumor growth studies. All animal experiments were approved by the
Institutional Animal Care and Use Committees of the RIKEN and were performed in accordance with the institutional guidelines.
Cells and Complete Media
B16F0 (ECACC, EC92101204) and B16F10 (ATCC, CRL-6475) cells were grown at 37C in 5%CO2 in a humidified incubator in RPMI-
1640 (Sigma Aldrich), supplemented with 10% FCS (Japan Bioserum), 100 mM nonessential amino acids (Sigma-Aldrich), 10 mM
HEPES (Sigma-Aldrich), 1 mM sodium pyruvate (GIBCO), 100 U/ml penicillin (GIBCO), 100 mg/ml streptomycin (GIBCO), 50 mM
2-mercaptoethanol (GIBCO) and 400 mM L-glutamine (Lonza). Cells were detached with trypsin-EDTA (GIBCO) and passaged every
3 days.
ILC2s (Lin-Sca1+c-Kit+ cells) were isolated from the mesentery as previously described (Moro et al., 2015) and cultured at 2,500
cells per well in 96-well round-bottom plates at 37C in 5% CO2 in a humidified incubator in RPMI-1640 (Sigma Aldrich), supple-
mented with 10% FCS (Japan Bioserum), 100 mM nonessential amino acids (Sigma-Aldrich), 10 mM HEPES (Sigma-Aldrich),
1 mM sodium pyruvate (GIBCO), 100 U/ml penicillin (GIBCO), 100 mg/ml streptomycin (GIBCO), 50 mM 2-mercaptoethanol (GIBCO)
in the presence of 10 ng/ml mIL-2 (R&D Systems). The medium was replenished every other day.
B16F10 cells were transfected with the short hairpin RNA (shRNA) constructs cloned into the pGFP-V-RS plasmids to specifically
knockdown expression of Ldha (Gene ID16828, OriGene). Untransfected cells (WT) and cells transfected with a non-specific, scram-
bled shRNA (CTRL) served as controls.
Human Samples




For tumor cell implantation, mice were anesthetized with 1% isoflurane in combination with O2 and N2. Tumor cells (1x10
6 cells per
mouse) alone or admixed with ILC2s (1x105 cells per mouse) in 100 mL PBS were inoculated subcutaneously and dorsolaterally. For
adipose tissue studies, tumor cells were inoculated into the anterior subcutaneous adipose tissue depot as previously described
(Wagner et al., 2012). Tumor-associated adipose tissue was collected bymicrodissection under a stereoscopic microscope. Control
adipose tissue from the counterpart depot was collected from age- and sex-matched animals. For IL-33 treatment, micewere admin-
istered IL-33 (0.5 mg in 100 mL PBS) or PBS alone intraperitoneally at the time of tumor implantation and every 3 days thereafter. For
NK cell depletion, mice were administered anti-asialo GM1 (ASGM1) antibody (0.3 mg in 100 mL PBS) or control IgG (0.3 mg in 100 mL
PBS) intraperitoneally the day before tumor implantation, at the time of tumor implantation and every 3 days thereafter. The depletion
efficiency was verified by flow cytometric analysis using spleen NK cells. Anti-ASGM1-treatedmice possessed 2.1% (±0.3%, s.e.m.)
CD3-NK1.1+ NK cells compared with 11.5% (±1.4%, s.e.m.) in control IgG-treatedmice. Themice were administered IL-33 or PBS as
previously described. Tumor size was measured daily using a vernier caliper.
Conditioned Medium Preparation
Conditioned medium (CM) was prepared from B16F10 cells (6x106 cells) plated into three 25 cm2 BD Falcon flasks (BD Biosciences).
Samples of CM were collected on days 1, 2, 3 and 4, transferred to 15 mL BD Falcon tubes (BD Biosciences) and centrifuged at
1300 rpm for 10 minutes as described elsewhere (Colegio et al., 2014). Samples were then sterile-filtered (0.22 mm) (Millipore) and
kept at 20C for future experiments.
Hanging Drop Culture for Spheroid Formation and Co-Culture with ILC2s
B16F0 or B16F10 cells were plated as hanging drops on an inverted culture dish lid in 25 mL of completemedium at 10,000 cells/drop.
The lid was then flipped and placed on a culture dish containing PBS to avoid evaporation. Hanging drop cultures were grown at 37C
up to 7 days in a humidified atmosphere with 5% CO2. The medium was changed after 4 and 6 days of the culture period. The gen-
eration of spheroids in hanging drops wasmonitored using a stereomicroscope. B16F0 or B16F10 spheroids (3 spheroids/well) were
then seeded in the bottom chamber, whereas ILC2s (25,000 cells/well) in the top chamber of a 6.5 mm (0.4 mm pore size) 24-well
transwell (Corning) in complete RPMI-1640medium in the presence of 10 ng/ml IL-2 (R&D Systems) and/or 10 ng/ml IL-33 (R&D Sys-
tems) for a period of 5 days. After 5 days of co-culture, ILC2s were collected and the number of viable cells counted in a haemocy-
tometer using the Trypan Blue exclusion method. The samemethod was applied for the assessment of the survival of ILC2s cultured
in CM or complete medium containing lactic acid, sodium lactate or HCl.e3 Cell Reports 30, 2743–2757.e1–e5, February 25, 2020
MTS Proliferation Assay
ILC2s were seeded into 96-well flat-bottom plates at a final density of 20,000 cells/well in 100 mL of medium supplemented with
10 ng/ml IL-2 (R&D Systems) and 10 ng/ml IL-33 (R&D Systems) with or without the presence of different concentrations of HCl, lactic
acid (Sigma Aldrich) and sodium lactate (Sigma Aldrich) or in 100 mL of CM and its derivatives supplemented with 10 ng/ml IL-2 (R&D
Systems) and 10 ng/ml IL-33 (R&D Systems). Unless stated otherwise, after 24 hours of incubation, each well was treated with 20 mL
of a solution composed of 1.9 mg/ml of MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2-tetrazo-
lium, inner salt; MTS] in PBS (pH 6.0). The plate was then incubated for an additional 1 hour. The absorbance of the soluble formazan
salt was measured against a tetrazolium standard, MTS solution.
Measurements of IL-5
IL-5 ELISA (Thermo Fisher Scientific) was performed as recommended by the manufacturer using supernatants of ILC2s seeded into
96-well round-bottom plates at a final density of 20,000 cells/well and cultured for 24 hours in 100 mL of medium supplemented with
10 ng/ml IL-2 (R&D Systems) and 10 ng/ml IL-33 (R&D Systems) with or without the presence of HCl, lactic acid (Sigma Aldrich) and
sodium lactate (SigmaAldrich) or in 100 mL of CMand its derivatives supplementedwith 10 ng/ml IL-2 (R&DSystems) and 10 ng/ml IL-
33 (R&D Systems).
Measurements of Lactic Acid
Cells were seeded into 96-well flat-bottom plates at a final density of 2,500 cells/well and cultured for 24 hours. Lactic acid concen-
tration was measured in medium using L-Lactate Assay Kit (Abcam) and following the manufacturer’s directions.
Giemsa Staining
Slides were coated with cell and tissue adhesive Cell-Tak (Corning) as recommended by the supplier. ILC2s cultured for 24 hours in
100 mL of medium supplemented with 10 ng/ml IL-2 (R&D Systems) alone or in combination with 10 ng/ml IL-33 (R&D Systems)
accompanied with the presence of lactic acid (Sigma Aldrich), sodium lactate (Sigma Aldrich), HCl or in 100 mL of CM and its deriv-
atives supplemented with 10 ng/ml IL-2 (R&D Systems) and 10 ng/ml IL-33 (R&D Systems) were transferred onto slides, washed,
dried, fixed with methanol (Sigma Aldrich) and stained with Giemsa (Muto). The diameter of ILC2s was determined from 100 cells/
group using NIS-elements AR software from Nikon.
Immunohistochemistry
Tumor or adipose tissue samples were collected and fixed in 4%paraformaldehyde, paraffin-embedded, and cut into 4 mm sections.
For immunolabeling, paraffin-embedded tissue sections were dewaxed, rehydrated and boiled in a water bath at 98C for 20-40 mi-
nutes in 10 mM citrate buffer (pH 6.0) or Tris/EDTA buffer (pH 9.0). Antigen retrieval for F4/80 staining was performed with Proteinase
K (Dako) treatment following the manufacturer’s instructions. The sections were then blocked with diluted serum from the secondary
antibody host for 30minutes, and incubated for 1 hour or overnight at 4Cwith the primary antibody. Endogenous peroxidase activity
was blocked for 30minutes with 3%hydrogen peroxide (Sigma-Aldrich) and a biotinylated anti-rat, anti-rabbit or anti-goat secondary
antibody (Vector Laboratories) was applied for 30 minutes. The antigen-antibody complex reaction was augmented with avidin-
biotin-peroxidase for 30 minutes following the manufacturer’s instructions (Vectastain Elite ABC HRP Reagent, Vector Laboratories)
and incubated for 1-10 minutes with diaminobenzidine tetrahydrochloride (DAB, Dako). Next, sections were counterstained with he-
matoxylin (Thermo Fisher Scientific), dehydrated, and mounted with Entellan (Merck). The following antibodies were used for immu-
nohistochemical analysis: rabbit anti-LYVE1 (1:250, catalog ab14917, Abcam), goat anti-CD31 (1:250, catalog sc1506, Santa Cruz
Biotechnology), rabbit anti-Perilipin1 (1:250, catalog 9349, Cell Signaling), rat anti-CD3 (CD3-12) (1:100, catalog ab11089, Abcam),
rabbit anti-CD8 (EPR21769) (1:1000, catalog ab217344, Abcam), rabbit anti-CD4 (EPR19514) (1:1000, catalog ab183685. Abcam),
rabbit anti-CD11b (1:4000, catalog ab75476, Abcam), rat anti-F4/80 (CI:A3-1) (1:250, catalog ab6640, Abcam), rat anti-CD301 (ER-
MP23) (1:100, catalog MCA2392, Bio-Rad), rabbit anti-MBP (AA100-215) (1:250, catalog ABIN1174871, Antibodies online), rabbit
anti-IL-33 (1:250, catalog PAB980Mu01, Cloud-Clone Corp) and rabbit anti-IL-33 (1:50, catalog MAB36252, R&D Systems).
Picrosirius Red Staining
Paraffin-embedded sections were deparaffinized and rehydrated. The slides were then stained with picrosirius red solution
composed of picric acid and Direct Red 80 (both Sigma-Aldrich) following the manufacturer’s instructions and dehydrated. Tissue
sections were then washed in 2 changes of acidified water after picrosirius red staining.
Flow Cytometry
Tumor samples were incubated in Collagenase D (1 mg/ml, Roche) for 1 hour at 37C followed by 100 mM EDTA and then mechan-
ically dissociated by passage through a 70 mm strainer to create a single-cell suspension. ILC2s were isolated from the mesenteric
and inguinal subcutaneous adipose tissue as previously described (Moro et al., 2010, 2015). To isolate cutaneous ILC2s, 1.53 1.5 cm
skin samples overlying tumors were incubated in Liberase TH (0.1 mg/ml, Roche) for 1 hour at 37C then mechanically dissociated
using gentleMACS (Miltenyi Biotec) and purified by density centrifugation with 30% Percoll (Sigma Aldrich). ILC2s from lymph nodes
were passaged through a 70 mm strainer. Isolated cells were suspended in HBSS containing 2% FBS and 0.2% sodium azide.Cell Reports 30, 2743–2757.e1–e5, February 25, 2020 e4
The following anti-mouse antibodies were used for flow cytometry: CD3ε (145-2C11), CD4 (GK1.5), CD8a (53-6.7), CD11c (HL3),
NK1.1 (PK136), CD19 (1D3), CD11b (M1/70), TER119 (TER119), Gr-1 (RB6-8C5), CD5 (53-7.3), Ly6A/E (Sca1) (D7 or E13-161.7),
KLRG1 (2F1), CD45.2 (104), c-Kit (2B8), Thy1.2 (53-2.1), T1/ST2 (DJ8), CD25 (APC/Cy7), Siglec-F (E50-2440) and fluorochrome-con-
jugated streptavidin were purchased fromBDBiosciences whereas antibodies againstmouse FcεRIa (MAR-1) were fromBioLegend.
Antibodies against mouse CD16/CD32 (2.4G2) were purified from hybridoma culture supernatants in our laboratory. Cell viability was
determined using propidium iodide. Cells were analyzed using FACSCalibur and sorted using FACSAria III. All data were analyzed
using FlowJo software (TreeStar). The gating strategy is provided as supplemental information (Figure S1). A hemocytometer-based
trypan blue dye exclusion cell quantitation was performed to estimate the total number of cells.
QUANTIFICATION AND STATISTICAL ANALYSIS
Database Analysis
The association between gene expression and survival rate of 458 melanoma patients was determined with recently described On-
colnc platform (www.oncolnc.org) using the publicly available TCGA (https://www.cancer.gov/about-nci/organization/ccg/research/
structural-genomics/tcga) database (Anaya, 2016). According to the expression level of IL33 or SIGLEC8, the 458 melanoma sam-
ples were assigned into two groups of low and high expression levels of IL33 or SIGLEC8, each of them containing 229 samples.
Expression data were extracted and the Kaplan–Meier estimation curve was plotted using Prism software (GraphPad Inc.).
The gene expression correlation analysis was performed on the ‘‘Tumour Skin CutaneousMelanoma - TCGA - 470 - rsem – tcgars’’
dataset containing data from 470 melanoma patients from the publicly available TCGA (https://www.cancer.gov/about-nci/
organization/ccg/research/structural-genomics/tcga) database using the microarray analysis and visualization platform R2
(https://hgserver1.amc.nl:443/). Pearson’s correlation coefficient, r, was calculated with the transform 2log setting. Expression
data of the genes of interest were extracted and represented using Prism software (GraphPad Inc.).
Statistics
Unless otherwise stated, results are representative of at least two independent experiments. Statistical significance was analyzed by
the unpaired, two-tailed Student’s t test or one-way ANOVA followed by Tukey’s multiple comparisons test using Prism software
(GraphPad Inc.). A p value less than 0.05 was considered to be statistically significant. p values less than 0.05, 0.01 or 0.001 were
labeled with *, ** or ***, respectively. Data were expressed as average ± s.e.m. Whenever possible, the investigator was partially
blinded for assessing the outcome (e.g., measurements in mouse studies and immunohistochemistry). To determine the correlation
between gene expression levels in skin cutaneous melanoma patients in the TCGA dataset, Pearson’s correlation coefficient, r, was
calculated. To demonstrate the association between gene expression levels and survival rate of skin cutaneousmelanoma patients in
the TCGA dataset, multivariate Cox regression and Kaplan–Meier analysis were performed. Expression data of the genes of interest
were extracted and the Kaplan–Meier estimation curve was plotted using Prism software (GraphPad Inc.).
DATA AND CODE AVAILABITY
This study did not generate any unique datasets or code.e5 Cell Reports 30, 2743–2757.e1–e5, February 25, 2020
